Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BID | P55957 | 3/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.33 |
| ▸ | F7 | P08709 | 3/20 | 0.33 |
| ▸ | F3 | P13726 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.33 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.33 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11193980 | 0.92 | SIGMAR1 (0.39) | SIGMAR1FDPSTSHRALOX15KDM4E | |
| SCHEMBL5983920 | 0.84 | FDPS (0.39) | SIGMAR1FDPSTSHRALOX15KDM4E | |
| SCHEMBL23159817 | 0.84 | SIGMAR1 (0.46) | SIGMAR1FDPSTSHRALOX15LIPG | |
| Hydrochloric Acid SCHEMBL7061051 | 0.82 | FDPS (0.38) | SIGMAR1FDPSALOX15CYP3A4CASP1 | |
| SCHEMBL23159850 | 0.82 | ALOX15 (0.47) | SIGMAR1FDPSTSHRALOX15LIPG | |
| Butanal SCHEMBL3772282 | 0.81 | ALDH1A1 (0.40) | SIGMAR1TSHRBIDBCL2L1MCL1 | |
| SCHEMBL11912455 | 0.78 | TAAR1 (0.47) | TSHRBIDBCL2L1MCL1BAK1 | |
| SCHEMBL10986621 | 0.78 | MGLL (0.56) | TSHRBIDBCL2L1MCL1BAK1 | |
| SCHEMBL11565109 | 0.78 | TAAR1 (0.47) | TSHRBIDBCL2L1MCL1BAK1 | |
| SCHEMBL5535994 | 0.78 | TAAR1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220125778-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-1562940-A2 | ARYL SULFONAMIDES | ChemoCentryx Inc (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050165067-A1 | Aryl sulfonamides | CHEMOCENTRYX | 2005-07-28 | — | — | US | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| US-20050137179-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2004085384-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040167113-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
| US-4518603-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1985-05-21 | — | — | US | disclosed |
| US-4480100-A | CHEMICAL INTERMEDIATES FOR ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125778-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, ENGASE | SIGMAR1 2209/4885FDPS 1447/4885TSHR 4484/4885 |
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | SIGMAR1 599/4885FDPS 2566/4885TSHR 1005/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | SIGMAR1 540/4885FDPS 3591/4885TSHR 1094/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | SIGMAR1 599/4885FDPS 2566/4885TSHR 1005/4885 |
| US-10899765-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | SIGMAR1 1516/4885FDPS 1953/4885TSHR 1442/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | SIGMAR1 2284/4885FDPS 1648/4885TSHR 4477/4885 |
| US-20050137179-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | SIGMAR1 270/4885FDPS 1548/4885TSHR 605/4885 |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, UGT2B7 | SIGMAR1 2504/4885FDPS 1830/4885TSHR 4350/4885 |
| US-20040167113-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | SIGMAR1 270/4885FDPS 1548/4885TSHR 605/4885 |
| US-20190169197-A1 | FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION | CCR2, CXCR2, CX3CR1 | SIGMAR1 1516/4885FDPS 1953/4885TSHR 1442/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | SIGMAR1 599/4885FDPS 2566/4885TSHR 1005/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | SIGMAR1 540/4885FDPS 3591/4885TSHR 1094/4885 |
| US-10208050-B2 | Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation | CCR2, CXCR2, CX3CR1 | SIGMAR1 1516/4885FDPS 1953/4885TSHR 1442/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | SIGMAR1 540/4885FDPS 3591/4885TSHR 1094/4885 |
| US-20050165067-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | SIGMAR1 599/4885FDPS 2566/4885TSHR 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.